Studies on Spanish and Italian NSCLC patients identified that driver mutations, such as EGFR, KRAS, and PIK3CA and ALK rearrangement, could coexist in these patients, and that targeted treatment might not be as effective in patients with these coexisting mutations [39]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.